| ID Source | ID |
|---|---|
| PubMed CID | 36354 |
| CHEMBL ID | 278581 |
| SCHEMBL ID | 828946 |
| MeSH ID | M0077941 |
| Synonym |
|---|
| st-567-br |
| alinidine |
| st-567 |
| 33178-86-8 |
| n-(2,6-dichlorophenyl)-n-prop-2-en-1-yl-4,5-dihydro-1h-imidazol-2-amine |
| alinidin |
| 2-(n-allyl-2,6-dichloroanilino)-2-imidazoline |
| 2-imidazoline, 2-(n-allyl-2,6-dichloroanilino)- |
| 2-(n-allyl-n-(2,6-dichlorophenyl)amino)-2-imidazoline |
| 1h-imidazol-2-amine, n-(2,6-dichlorophenyl)-4,5-dihydro-n-2-propenyl- |
| brn 0961200 |
| alinidina [inn-spanish] |
| alinidinum [inn-latin] |
| NCGC00162175-02 |
| NCGC00162175-01 |
| NCGC00162175-03 |
| st 567 br (as hbr) |
| st 567-br (as hbr) |
| st-567-br-(as-hbr) |
| CHEMBL278581 |
| st 567-br [as hydrobromide] |
| n-(2,6-dichlorophenyl)-n-prop-2-enyl-4,5-dihydro-1h-imidazol-2-amine |
| dtxsid4022571 , |
| cas-33178-86-8 |
| tox21_112002 |
| dtxcid702571 |
| cas_33178-86-8 |
| bdbm85231 |
| alinidina |
| alinidinum |
| e7idj8ds1d , |
| 5-25-09-00280 (beilstein handbook reference) |
| alinidine [inn:ban] |
| unii-e7idj8ds1d |
| n-(2,6-dichlorophenyl)-4,5-dihydro-n-2-propenyl-1h-imidazol-2-amine |
| LP00514 |
| SCHEMBL828946 |
| st 567 br (as hydrobromide) |
| alinidine [inn] |
| alinidine [mi] |
| alinidine [mart.] |
| st 567-br (as hydrobromide) |
| st-567-br-(as-hydrobromide) |
| alinidine [who-dd] |
| 2-[n-allyl-n-(2,6-dichloro-phenyl)-amino]-2-imidazoline |
| allindine |
| n-allyl-n-(2,6-dichlorophenyl)-4,5-dihydro-1h-imidazol-2-amine # |
| AKOS028110641 |
| n-allyl-n-(2,6-dichlorophenyl)-4,5-dihydro-1h-imidazol-2-amine |
| J-019070 |
| FT-0713597 |
| Q4726779 |
| SDCCGSBI-0633723.P001 |
| Excerpt | Reference |
|---|---|
| "Alinidine is a new drug which reduces heart-rate in animals by an unknown mechanism. " | ( Harron, DW; Riddell, JG; Shanks, RG, 1981) |
| "Alinidine is a new sinus node inhibitor which does not interact with the beta adrenergic receptors. " | ( Hugenholtz, PG; Simoons, ML, 1984) |
| "Alinidine is a recently developed antiarrhythmic medication that acts directly on the cardiac pacemaker cells to reduce heart rate (HR). " | ( Moulart, D; Preiser, JC; Vincent, JL, 1992) |
| "Alinidine is a new bradycardic agent that interferes with ion channels and the if pacemaker current. " | ( Caucheteux, D; Gurné, O; Hanet, C; Hue, L; Maldague, P; Pouleur, H; Rousseau, MF, 1989) |
| "Alinidine appears to be a safe drug for reduction of heart rate in patients with unstable angina and acute myocardial infarction." | ( Simoons, ML, 1987) |
| "Alinidine is a bradycardic agent, which appears to be of potential value in the therapy of coronary heart disease. " | ( Kreuzer, H; Wiegand, V, 1987) |
| "Alinidine appears to be a suitable drug for control of inappropriate sinus tachycardia in patients with heart disease undergoing surgery." | ( Skarvan, K, 1987) |
| "Alinidine is a new bradycardic agent which has been shown to be beneficial in the treatment of coronary heart disease. " | ( Friedrich, T; Hoffmann, M; Huckauf, H; Kammradt, G; Lichey, J, 1986) |
| Excerpt | Reference |
|---|---|
| "Alinidine has been investigated for a possible mode of action in guinea-pig atria. " | ( Scholtysik, G, 1982) |
| "Alinidine has no negative inotropic action and has no effect on the linear relation between extracellular Ca and force of myocardial contraction." | ( Millar, JS; Williams, EM, 1981) |
| "Alinidine has no beta-blocking, muscarinic or quinidine-like properties." | ( Friedrich, T; Hoffmann, M; Huckauf, H; Kammradt, G; Lichey, J, 1986) |
| "Thus alinidine has direct negative chronotropic effects, no effect on sinus node responses to sympathetic stimulation, ability to diminish sinus node and AV junctional responses to vagal stimulations without interference at the cholinergic muscarinic receptor, and 4) no effect on AV nodal conduction." | ( Hageman, GR; James, TN; Neely, BH; Urthaler, F, 1985) |
| Excerpt | Reference |
|---|---|
| "Alinidine did not increase resting potential or accelerate repolarisation, suggesting that potassium conductance was not increased." | ( Millar, JS; Williams, EM, 1981) |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 11.8832 | 0.0002 | 29.3054 | 16,493.5996 | AID743079 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 7.9433 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 23.7781 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1347050 | Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID1347045 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID588378 | qHTS for Inhibitors of ATXN expression: Validation | |||
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1347049 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID588349 | qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay | |||
| AID504836 | Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation | 2002 | The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16 | Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID175392 | Dose required to decrease heart rate after iv injection to spinal rats | 1980 | Journal of medicinal chemistry, Nov, Volume: 23, Issue:11 | Chemistry, pharmacology, and structure-activity relationships with a new type of imidazolines exerting a specific bradycardic action at a cardiac site. |
| AID197543 | Antagonistic activity in the rat thoracic aorta | 2001 | Journal of medicinal chemistry, May-24, Volume: 44, Issue:11 | Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress. |
| AID24224 | Partition coefficient (logD7.4) | 1980 | Journal of medicinal chemistry, Nov, Volume: 23, Issue:11 | Chemistry, pharmacology, and structure-activity relationships with a new type of imidazolines exerting a specific bradycardic action at a cardiac site. |
| AID189698 | Evaluated for decreased heart rate in spinal rats, relative activity was determined | 1980 | Journal of medicinal chemistry, Nov, Volume: 23, Issue:11 | Chemistry, pharmacology, and structure-activity relationships with a new type of imidazolines exerting a specific bradycardic action at a cardiac site. |
| AID25620 | Dissociation constant (pKa) | 1980 | Journal of medicinal chemistry, Nov, Volume: 23, Issue:11 | Chemistry, pharmacology, and structure-activity relationships with a new type of imidazolines exerting a specific bradycardic action at a cardiac site. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 92 (68.66) | 18.7374 |
| 1990's | 26 (19.40) | 18.2507 |
| 2000's | 8 (5.97) | 29.6817 |
| 2010's | 4 (2.99) | 24.3611 |
| 2020's | 4 (2.99) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 22 (14.86%) | 5.53% |
| Reviews | 7 (4.73%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 119 (80.41%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Article | Year |
|---|---|
| Safety and efficacy of alinidine in symptom-free asthmatics. European journal of clinical pharmacology, Volume: 31, Issue: 4 | 1986 |
| [information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | |
| Article | Year |
|---|---|
| Alinidine pharmacokinetics following acute and chronic dosing. British journal of clinical pharmacology, Volume: 13, Issue: 6 | 1982 |
| An assessment of the contribution of clonidine metabolised from alinidine to the cardiovascular effects of alinidine. British journal of clinical pharmacology, Volume: 16, Issue: 4 | 1983 |
| [information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | |
| Article | Year |
|---|---|
| Proof of the linearity of the pharmacokinetics of alinidine in man. European journal of clinical pharmacology, Volume: 21, Issue: 3 | 1981 |
| Alinidine pharmacokinetics following acute and chronic dosing. British journal of clinical pharmacology, Volume: 13, Issue: 6 | 1982 |
| Effect of dobutamine on cardiac function in man: reciprocal roles of heart rate and ventricular stroke volume. Critical care medicine, Volume: 10, Issue: 6 | 1982 |
| Relative roles of heart rate and ventricular stroke volume for the regulation of cardiac output during controlled hypotension with sodium nitroprusside in man. European journal of clinical investigation, Volume: 12, Issue: 1 | 1982 |
| [information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | |
| Article | Year |
|---|---|
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology, Volume: 96, Issue: 5 | 2019 |
| Development and quality control of a highly sensitive radioimmunoassay for alinidine. Journal of pharmacological methods, Volume: 6, Issue: 2 | 1981 |
| [information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | |